Compare Caesars Entertainment Inc (CZR) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Caesars Entertainment Inc vs Enveric Biosciences Inc — how do they compare? Caesars Entertainment Inc trades at $29.89 (market cap $6.08B), while Enveric Biosciences Inc trades at $1.28 (market cap $5.32M). The key difference: Caesars Entertainment Inc is far larger — about 1142.9× Enveric Biosciences Inc's market cap, and Caesars Entertainment Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| CZR | ENVB | |
|---|---|---|
Market Cap | $6.08B | $5.32M |
Sector | Consumer Cyclical | Health |
52-Week High | $30.41 | $17.40 |
52-Week Low | $18.14 | $1.28 |
Enterprise Value | $30.14B | $408.82K |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Caesars Entertainment (CZR) trades at $29.66, down 0.6% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company faces fundamental challenges with three consecutive quarterly earnings misses and negative net income margins, though valuation ratios appear attractive with P/E of 10.42 and P/S of 0.53. Recent developments include the opening of Caesars Republic Lake Tahoe and a pending $17.6 billion acquisition by Fertitta Entertainment.
CZR presents a complex investment case with analyst consensus leaning cautious (33% buy, 67% hold) despite a $31.27 price target suggesting modest upside. The pending acquisition provides a potential floor, but ongoing profitability challenges and competitive pressures in the gaming sector warrant careful monitoring of Q2 2026 earnings due July 28, 2026.
ENVB trades at $1.33, down 1.48% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company shows significant financial challenges with negative ROE of -257.95% and ROA of -218.01%, though it has consistently beaten earnings expectations in recent quarters. Recent news highlights active participation in investor conferences and progress with EB-003 drug candidate development.
While analyst consensus is 75% buy-rated, the stock faces substantial fundamental risks from negative profitability and cash burn. Investment opportunity exists if clinical developments succeed, but shareholders should weigh high operational losses against potential biotech breakthroughs in the neuroplastogenic therapeutics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
